NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

** HEALTH RESEARCH SHOWCASE THURSDAY 29 MAY 2025 **

News

You are here: Home > Metabolic Experimental Medicine > Oxford receives European funding for paediatric diabetes research

Oxford receives European funding for paediatric diabetes research

14 November 2023 · Listed under Metabolic Experimental Medicine

Oxford researchers have received funding from a European programme to investigate how to best follow up children who are at risk of type 1 diabetes (T1D).

Doctor,Taking,Blood,Test,From,Small,Patient.
The funding will allow the Oxford BRC diabetes team to build on existing programmes (Shutterstock.com)

Oxford will receive 433,000 euros as part of the EDENT1FI programme which aims to identify T1D at its pre-clinical stage in children in the general population.

Dr Rachel Besser, a paediatric diabetes consultant at Oxford University Hospitals NHS Foundation Trust and researcher at the University of Oxford’s Wellcome Centre for Human Genetics, is leading the Oxford workstream.

As part of the EDENT1FI project, Dr Besser’s team will implement an acceptable and feasible follow-up programme in children and adolescents with stage 1 and stage 2 T1D; and investigate novel metabolic and glycaemic approaches to monitor children with early-stage T1D.

Dr Besser, whose work is supported by the NIHR Oxford Biomedical Research Centre (BRC), said: “We are delighted to receive this funding and to be part of a major international collaboration tackling type 1 diabetes in young people. We will be exploring new approaches to follow up and monitor children with early-stage T1D or at risk of developing the disease.”

“Identifying children and monitoring them is vital if we are to prevent life threatening illness and to identify children eligible for any preventative therapies.”

Capture Rachel Besser

The funding will allow Dr Besser (pictured left) to build on existing programmes, including an NIHR programme development grant assessing acceptability, feasibility and cost effectiveness of screening in childhood T1D; and an Oxford BRC proof of concept study to assess the ability to screen children for T1D risk at the time of their pre-school vaccination.

EDENT1FI (European action for the Diagnosis of Early Non-clinical Type 1 diabetes For disease Interception) is a global consortium comprising 28 partners across 12 countries, bringing together academic researchers, industry leaders and charities combat T1D with the support of a €22 million grant from the European Union’s Innovative Health Initiative (IHI). The project is funded through the Horizon Europe programme and is set to run over five years.

← Rapid weight loss found to be safe and helpful for people with liver disease
Blood collected through skin offers reliable testing method in children with type 1 diabetes →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre